Duloxetine-related posterior reversible encephalopathy syndrome: A case report

Medicine (Baltimore). 2016 Aug;95(33):e4556. doi: 10.1097/MD.0000000000004556.

Abstract

Background: Posterior reversible encephalopathy syndrome (PRES) has well-established links with several drugs. Whether a link also exists with serotonin-norepinephrine reuptake inhibitor such as duloxetine is unclear.

Methods: We report on a patient who developed PRES with a coma and myoclonus related to hypertensive encephalopathy a few days after starting duloxetine treatment. Magnetic resonance imaging was performed and catecholamine metabolites assayed.

Results: The patient achieved a full recovery after aggressive antihypertensive therapy and intravenous anticonvulsant therapy.

Conclusions: The clinical history, blood and urinary catecholamine and serotonin levels, and response to treatment strongly suggest that PRES was induced by duloxetine. Duloxetine should be added to the list of causes of PRES.

Publication types

  • Case Reports

MeSH terms

  • Aged, 80 and over
  • Antidepressive Agents / adverse effects*
  • Antidepressive Agents / therapeutic use
  • Depression / drug therapy
  • Duloxetine Hydrochloride / adverse effects*
  • Female
  • Humans
  • Neuroimaging
  • Posterior Leukoencephalopathy Syndrome / chemically induced*
  • Posterior Leukoencephalopathy Syndrome / diagnostic imaging
  • Tomography, X-Ray Computed

Substances

  • Antidepressive Agents
  • Duloxetine Hydrochloride